A randomized controlled trial of intravenous magnesium sulphate as an adjunct to standard therapy in atrial fibrillation
, , , , e | 23 ago 2022
INFORMAZIONI SU QUESTO ARTICOLO
Pubblicato online: 23 ago 2022
Pagine: 91 - 101
Ricevuto: 14 apr 2022
Accettato: 04 giu 2022
DOI: https://doi.org/10.2478/acm-2022-0011
Parole chiave
© 2022 Raghu K. et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Fig.1
Fig. 2
Fig. 3
Comparison of Basic characteristics between the two groups
| Characteristics | MgSO4 | Placebo |
|---|---|---|
| No randomized (n) | 41 | 14 |
| Sex | ||
| Male (%) | 41.46 % | 0.71 % |
| Female | 58.53 % | 92 % |
| Age, yrs., Range | 72.0 (50 – 70) | 73.0 (51 – 71.0 ) |
| History of Alcohol Abuse (%) | 51.95 % | 72 % |
| History of Antiarrhythmic Use | 77% | 33% |
| History of RHD (%) | 19.51 % | 28.57 % |
| History of CAD (%) | 17.07 % | 21.42 % |
| History of Hypothyroid (%) | 9.75 % | 21.42 % |
| Currently receiving Antiarrhythmic drugs (%) | 1.07 % | 21.42 % |
| Duration of Symptoms: | ||
| Within 24 hr (n) | 41 | 14 |
| After 24 hr (n) | 1 | 14 |
| ECG after 24 hrs – Rate (Mean) | 84.51 | 112.2 |
| Rhythm (%) | NSR (65%) | AF (85%) |
| ICU Stay (Mean) | 2.25 days | 4.25 days |
Minimum adverse effects after drug administration
| Frequency | Percent | Valid Percent | Cumulative Percent | P value | ||
|---|---|---|---|---|---|---|
| Valid | MgSO4 | 5 | 12.2 | 12.2 | 12.2 | – |
| Placebo | 2 | 14.3 | 14.3 | 14.3 | – | |
| CROSS TABULATION | ||||||
| Drug Administration/ Adverse effects | Adverse | effects | Total | |||
| 1.00 | 2.00 | |||||
| DRUG Administration | MgSO4 | Count % Within DRUG Administration | 512.2% | 36 87.8% | 41 100.0% | 0.839 |
| % Within DRUG adverse effects | 71.4% | 75% | 74.5% | |||
| % Of total | 9.1% | 65.5% | 74.5% | |||
| Placebo | Count | 2 | 12 | 14 | ||
| % Within DRUG Administration | 14.3 | 85.7% | 100% | |||
| % Within DRUG adverse effects | 28.6% | 25.0% | 25.5% | |||
| % Of total | 3.6% | 21.8% | 25.5% | |||
| Total | Count | 7 | 48 | 55 | ||
| % Within DRUG Administration | 12.7% | 87.3% | 100% | |||
| % Within DRUG adverse effects | 100% | 100% | 100% | |||
| % Of total | 12.7% | 87.3% | 100% | |||
Measurement of effect of MgSO4 using ECG and pulse rate
| Mean | S.D | S.E | 95% CI | P value | |
|---|---|---|---|---|---|
| Drugs Given | |||||
| Mgso4 | 1.8585 | 0.11175 | 0.01745 | – | <0.0001 |
| Placebo | 1.8929 | 0.09169 | 0.02450 | ||
| ECG rate at presentation | |||||
| Mgso4 | 84.5122 | 8.54729 | 1.33486 | – | <0.0001 |
| Placebo | 112.2857 | 7.89770 | 2.11075 | ||
| ECG Rhythm At 24hrs | |||||
| Mgso4 | 74.5 | 4.58 | – | ||
| Placebo | 25.5 | 3.45 | – | ||
| Heart Rate | |||||
| At Presentation to ED | Mean Pulse rate difference, Beats/Min (95% CI) | ||||
| MgSO4 | 162.7561 | 25.12845 | 3.92440 | 154.8246-170.6876 | 0.015 |
| Placebo | 177.2143 | 16.02008 | 4.28155 | 167.9646-186.464 | |
| After 30 minutes | |||||
| MgSO4 | 159.3902 | 23.75 | 3.70 | -12.60 (-26.32 – 1.10) | |
| Placebo | 172.0000 | 15.92 | 4.25 | 0.071 | |
| After 60 minutes | |||||
| MgSO4 | 147.6829 | 19.63 | 3.066 | -12.60 (-24.07 – -1.12) | 0.032 |
| Placebo | 160.2857 | 14.35 | 3.836 | ||
| After 90 minutes | |||||
| MgSO4 | 129.9756 | 14.218 | 2.22 | -18.31 (-27.10 – -9.51) | 0.001 |
| Placebo | 148.2857 | 13.980 | 3.736 | ||
| After 120 minutes | |||||
| MgSO4 | 111.2195 | 8.802 | 1.374 | -23.85 (-30.53 – -12.16) | 0.001 |
| Placebo | 135.07 | 15.304 | 4.09 | ||
| After 150 minutes | |||||
| MgSO4 | 96.1220 | 5.58 | 0.87 | -27.94 (-33.29 – -13.60) | 0.001 |
| Placebo | 24.07 | 14.34 | 3.83 | ||
| Paired Test of Heart Rate after 30 Mins & 150 Mins | |||||
| Mean | Std dev | Std Err | 95% CI | P | |
| After 30 minutes | 162.6 | 22.57 | 3.044 | 53.77-64.95 | <0.0001 |
| After 150 minutes | 103.23 | 14.955 | 2.01 | ||
Descriptive statistics of the patient characteristics
| N | Minimum | Maximum | Sum | Mean | std | ||
|---|---|---|---|---|---|---|---|
| Statistic | Statistic | Statistic | Statistic | Statistic | Std error | Statistic | |
| Age | 55 | 32 | 80 | 2981 | 54.2 | 1.62 | 12.05 |
| Heart rate at presentation | 55 | 124 | 212 | 9154 | 166.43 | 3.219 | 23.87 |
| MgSO4 | 55 | 1.7 | 2.1 | 102.7 | 1.867 | 0.014 | 0.107 |
| After 30 minutes | 55 | 125 | 201 | 8943 | 162.6 | 3.044 | 22.57 |
| After 60 minutes | 55 | 120 | 185 | 8299 | 150.9 | 2.57 | 19.12 |
| After 90 minutes | 55 | 107 | 169 | 7405 | 134.6 | 2.18 | 16.17 |
| After 120 minutes | 55 | 99 | 151 | 6451 | 117.29 | 2.016 | 14.95 |
| After 150 minutes | 55 | 89 | 147 | 5678 | 103.23 | 2.016 | 14.95 |
| ECG Rate 24Hr | 55 | 72 | 127 | 5037 | 91.58 | 1.99 | 14.77 |
| ICU stay | 55 | 1.0 | 6.0 | 124 | 2.25 | 0.17 | 1.322 |